GEHC
GE HealthCare Technologies Inc.
$70.23
+0.67% 2026-10-20
Health CareS&P 500
GEHCSPY
1W
+2.1%
1M
+9.5%
3M
+13.3%
6M
-2.8%
YTD
-14.3%
1Y
-6.8%
Live chart
Loading live chart…
Grades vs sector
Momentum19th pct in sectorD
Momentum
19th pct in sector
12-1 return: -12.7%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth35th pct in sectorC-
Growth
35th pct in sector
Revenue growth (YoY): +5.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value73rd pct in sectorB+
Value
73rd pct in sector
Forward E/P: 7.8% · EBITDA/EV: 9.0%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability64th pct in sectorB
Profitability
64th pct in sector
Profit margin: +9.3% · Return on equity: +19.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 377 of 499 · 12-1 momentum % -5.0
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsGE Healthcare Technologies Launches Global Evaluation Program for StarGuide GX System
MT Newswires · 16h ago
GE HealthCare announces five new global collaborations to advance the next generation of theranostics imaging
Business Wire · 16h ago
GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe
Zacks · 20h ago
GE HealthCare expands general imaging ultrasound portfolio with LOGIQ Focus, elevating everyday ultrasound performance
Business Wire · Oct 19
GE HealthCare Technologies (GEHC) Could Be 19% Undervalued As Imaging Push Gains Ground
Simply Wall St. · Oct 17
Key stats
Market cap$31.7B
P/E (trailing)16.1
P/E (forward)13.0
52-week range58.75 – 89.77
Revenue growth (YoY, latest qtr)+5.8%
Dividend yield0.23%
Analyst consensusBuy (20)
Mean price target$82.70 (+18%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
No cash-flow valuation
Model read-out from the numbers below, not advice. Score +0 (DCF counts double).
▲Forward P/E vs sector13.0x vs median 17.6x
▼Piotroski F-score3/9
▼Altman Z1.8 (distress)
•Net debt / EBITDA3.0x
▲Analyst target+18% (20 analysts)
Discounted cash flow
Trailing free cash flow is negative or missing, so a cash-flow DCF isn't meaningful by default. You can enter your own assumptions below.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Not enough data to run a reverse DCF.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-03-31). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 0.85 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 18th pct
16.1×cheaper
Forward P/E
cheaper
sector median 17.6× · 30th pct
13.0×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 42nd pct
14.9×cheaper
Price / sales
cheaper
sector median 3.1× · 24th pct
1.5×cheaper
Price / book
cheaper
sector median 3.5× · 43rd pct
3.0×cheaper
FCF yield
sector median 4.1%
–Forward EPS $5.41 vs trailing $4.35 (+24% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$15.8B
as of 2026-03-31
vs a year ago
+6%
YoY
× TTM revenue
0.75×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
39.1%
Operating margin
12.6%
FCF margin
–
Net margin
9.1%
Return on equity
17.9%
Return on invested capital
10.9%
Net debt / EBITDA
3.0×
Current ratio
1.2×
Interest cover
–
Cash conversion (OCF/NI)
–
Piotroski F-score 3/9 · last two fiscal years
✓ Positive net income✗ Positive operating cash flow✗ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✗ Asset turnover improved
Altman Z-score 1.8 (distress zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$83
+18%
Analysts
20
Buy
Range
$70–$96
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $20.6B | $2.1B | – |
| 2024 | $19.7B | $2.0B | – |
| 2023 | $19.6B | $1.6B | – |
| 2022 | $18.3B | $1.9B | – |
| 2021 | $17.6B | $2.2B | – |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +4.0%.
Earnings
Next report: 2026-10-28 · before open · EPS est 1.21
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | 1.04 | 1.13 | +9.1% |
| 2026-04-29 | 1.05 | 0.99 | -5.7% |
| 2026-02-04 | 1.40 | 1.44 | +3.0% |
| 2025-10-29 | 1.05 | 1.07 | +2.2% |
| 2025-07-30 | 0.92 | 1.06 | +15.5% |
| 2025-04-30 | 0.91 | 1.01 | +10.6% |
| 2025-02-13 | 1.26 | 1.45 | +14.8% |
| 2024-10-30 | 1.05 | 1.14 | +8.3% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $5.3B | +5.8% |
| 2026-03-31 | $5.1B | – |
| 2025-12-31 | $5.7B | – |
| 2025-09-30 | $5.1B | – |
| 2025-06-30 | $5.0B | – |
Analyst actions
BTIG
PT $75
2026-10-12 · main
Buy → BuyPT $75
Barclays
PT $85
2026-10-07 · init
→ OverweightPT $85
Citigroup
PT $71
2026-10-05 · main
Neutral → NeutralPT $71
Needham
PT $93
2026-10-05 · reit
Buy → BuyPT $93
Needham
PT $93
2026-09-22 · init
→ BuyPT $93
BTIG
PT $79
2026-09-17 · reit
Buy → BuyPT $79
Recent dividends
2026-07-24: $0.035 · 2026-04-02: $0.035 · 2026-01-09: $0.035 · 2025-10-24: $0.035 · 2025-07-25: $0.035 · 2025-04-25: $0.035 · 2025-01-14: $0.035 · 2024-10-18: $0.030
Insider trades
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:03:11 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.